When you undergo medical stem cell treatment in Japan, the process is highly regulated, standardized, and backed by specific laws that differ from many other countries. The first step is always a detailed consultation and screening, where your medical history, current condition, and imaging data (like MRI or CT scans) are reviewed by a licensed physician. This is not a walk-in procedure; you must have a documented medical need, such as osteoarthritis, spinal cord injury, or autoimmune conditions, and the clinic must confirm that you are a suitable candidate based on their internal protocols and the Act on Safety of Regenerative Medicine (ASRM), which was enacted in 2014. The clinic will explain the specific type of stem cells they plan to use—typically autologous (your own) mesenchymal stem cells (MSCs) derived from adipose tissue (fat) or bone marrow, or sometimes allogeneic (donor) cells from umbilical cord tissue. You will sign detailed informed consent forms that outline the risks, benefits, and the fact that the treatment is not covered by national health insurance.
After approval, the next step is cell harvesting. If you are using your own adipose-derived stem cells, a minor liposuction procedure is performed under local anesthesia. The doctor will extract about 50 to 100 milliliters of fat tissue, usually from your abdomen or thigh. This takes about 30 minutes and is done in an outpatient setting. For bone marrow-derived stem cells, the process involves aspiration from the iliac crest (hip bone) under local anesthesia or light sedation, extracting about 60 to 120 milliliters of bone marrow. The harvested tissue is immediately sent to a certified cell processing center (CPC) that is licensed by the Ministry of Health, Labour and Welfare (MHLW). These centers must follow Good Manufacturing Practice (GMP) standards, and the entire process is documented to ensure sterility and cell viability. The cells are then isolated, cultured, and expanded in a sterile laboratory over a period of 2 to 4 weeks. During this culture phase, the cells are tested for sterility, endotoxin levels, and cell count. A typical dose for a single treatment is between 50 million and 200 million cells, depending on the condition being treated.
Once the cells are ready, the administration step begins. The most common route of delivery is intravenous (IV) infusion, where the stem cells are suspended in a saline solution and infused over 30 to 60 minutes. This is used for systemic conditions like autoimmune diseases or general anti-aging. For orthopedic issues, such as knee osteoarthritis or joint injuries, the cells are injected directly into the affected joint under ultrasound or fluoroscopic guidance. For neurological conditions, such as spinal cord injury or stroke, the cells may be administered via intrathecal injection (into the spinal fluid) or directly into the damaged tissue during a surgical procedure. The clinic monitors your vital signs during and immediately after the infusion. Side effects are typically mild, including headache, fever, or injection site pain, which resolve within 24 to 48 hours. Serious adverse events are rare but are reported to the Pharmaceuticals and Medical Devices Agency (PMDA).
Post-treatment follow-up is a critical part of the process. You will be required to have scheduled check-ups at 1 month, 3 months, 6 months, and 12 months after the procedure. These follow-ups include blood tests, imaging (if applicable), and functional assessments to measure improvement. The clinic will document your progress and report any significant outcomes to the MHLW as part of their ongoing compliance with the ASRM. The cost of a single treatment cycle in Japan typically ranges from 1.5 million to 4 million Japanese yen (approximately $10,000 to $28,000 USD), depending on the clinic, the number of cells, and the complexity of the administration. This cost is not covered by Japanese health insurance, so you must pay out-of-pocket or through a medical tourism package.
It is crucial to understand that the Japanese regulatory framework requires that all stem cell treatments be performed under a Certified Regenerative Medicine Plan submitted to the MHLW. This plan must include the type of cells, the target disease, the treatment protocol, and the safety monitoring plan. The clinic is required to submit annual reports. This means that any clinic operating legally in Japan has a publicly available plan number that you can verify. For a more detailed breakdown of the entire journey, including clinic selection, legal requirements, and what to expect during each phase, you can read the Japan Medical stem cell treatment process in Japan explained.
The table below summarizes the key steps and their typical timelines:
| Step | Procedure | Typical Duration | Key Regulatory Requirement |
|---|---|---|---|
| 1. Consultation & Screening | Medical history review, imaging, blood tests, informed consent | 1-2 days | Verification of indication under ASRM |
| 2. Cell Harvesting | Liposuction or bone marrow aspiration | 30-60 minutes | Performed in a licensed clinic |
| 3. Cell Processing & Culture | Isolation, expansion, sterility testing in a GMP-certified CPC | 2-4 weeks | MHLW-approved processing center |
| 4. Administration | IV infusion, intra-articular, intrathecal, or surgical injection | 30-90 minutes | Performed under a Certified Regenerative Medicine Plan |
| 5. Follow-up | Clinical assessments, blood tests, imaging at 1, 3, 6, 12 months | Up to 12 months | Annual reporting to MHLW |
Another important factor is the source of the stem cells. In Japan, the use of induced pluripotent stem cells (iPSCs) is also regulated, but they are primarily used in clinical research settings rather than routine commercial treatments. Most commercial clinics use mesenchymal stem cells (MSCs) because they have a strong safety profile and are not associated with the tumorigenic risks that iPSCs carry. The MSCs used in Japan are typically from the umbilical cord (allogeneic) or from the patient's own fat or bone marrow. The allogeneic cells are sourced from registered donors who undergo rigorous screening for infectious diseases, genetic disorders, and other health conditions. The cell bank must be registered with the MHLW, and each batch of cells is tested for sterility, mycoplasma, and endotoxins before release.
Data from the Japanese Ministry of Health shows that as of 2023, over 1,200 regenerative medicine plans have been submitted and approved under the ASRM, covering a wide range of conditions. The most common conditions treated include osteoarthritis (approximately 35% of plans), spinal cord injury (15%), and autoimmune diseases (10%). The success rates vary widely by condition. For knee osteoarthritis, clinical studies published in Japanese medical journals report that 60% to 80% of patients experience significant pain reduction and improved function at 6 months post-treatment. For spinal cord injury, the data is more modest, with about 30% to 40% of patients showing some improvement in motor or sensory function. The key is that these results are based on patient-reported outcomes and objective measures like the Visual Analog Scale (VAS) for pain and the Knee Injury and Osteoarthritis Outcome Score (KOOS) for joint function.
You should also be aware of the legal restrictions for foreign patients. Japan does not have a specific medical visa for stem cell treatment, but you can enter on a standard tourist visa (for stays up to 90 days) or a medical stay visa (for longer treatments). The clinic must provide a letter of invitation and a treatment plan for your visa application. You must also have travel insurance that covers the cost of any complications, as the Japanese healthcare system will not cover foreign patients for stem cell procedures. The clinic will typically require a deposit of 30% to 50% of the total cost before the procedure, with the balance due upon completion. The total cost for a full treatment cycle, including harvesting, processing, administration, and follow-up, is usually quoted in a single package price.